题名

非瓣膜性心房顫動病人使用新型抗凝血劑現況及成效分析

并列篇名

Patterns and Outcomes of Novel Oral Anticoagulants in Real-World Patients with Non-Valvular Atrial Fibrillation

DOI

10.6342/NTU201602051

作者

黃馨儀

关键词

新型口服抗凝血劑 ； 亞洲 ； 心房顫動 ； dabigatran ； rivaroxaban ； warfarin ； 健保資料庫 ； Novel oral anticoagulants (NOACs) ； Asian ； atrial fibrillation ； dabigatran ； rivaroxaban ； warfarin ； National Health Insurance Research Database (NHIRD)

期刊名称

國立臺灣大學臨床藥學研究所學位論文

卷期/出版年月

2016年

学位类别

碩士
导师

王繼娟
内容语文

英文
中文摘要

背景:近年來新型口服抗凝血劑(NOAC)開始應用於非瓣膜性心房顫動的病人來預 防中風,然而在臨床應用的療效及安全性仍是需進一步研究的議題。 目的:分析新型口服抗凝血劑開始應用於台灣後,影響整體抗血栓藥物的開方結構 及應用於臨床上的療效及安全性。 方法: 利用台灣健保資料庫分析從 2012 年 6 月至 2015 年 12 月使用 dabigatran、 rivaroxaban 或 warfarin 的心房顫動的病人。我們利用傾向分數配對的方法來平衡 兩個分析的族群,及利用 Cox 比例風險模式來計算兩個分析族群間發生事件的風 險。我們分析病人直到最早的事件發生、停藥、換藥或 2015 年 12 月的最後一天。 結果: 相較於 warfarin,NOAC 有比較低的顱內出血(HR: 0.45, 95% CI: 0.31-0.66) 、 靜脈栓塞(HR: 0.37, 95% CI: 0.21-0.66)、及綜合出血(HR: 0.8, 95% CI: 0.69-0.92)風 險。然而,腸胃道出血的出血在兩組之間則沒有顯著的差異。在次群組分析中, rivaroxaban 20 毫克及 15 毫克相較於 warfarin 有較低的缺血性中風的風險,而我們 在 rivaroaban 20 毫克亦發現其腸胃道出血的風險較 warfarin 來得低(HR:0.47, 95% CI: 0.24-0.90)。Rivaroxaban 應用在 65 歲及 80 歲以上的老人相較於 warfarin,其預 防缺血性中風的效果較佳。 結論: 新型口服抗凝血劑相較於 warfarin 有較低的顱內出血的風險。另外, rivaroxaban 的劑量或許需大於 15 毫克以上才是預防缺血性中風的有效劑量。再者, rivaroxaban 在老年族群中相較於 warfarin 可能是比較好的選擇。
英文摘要

Background: Novel oral anticoagulants (NOACs) recently launched to Taiwan for preventing ischemic stroke among non-vavluar atrial fibrillation patients. However, the effectiveness and safety in real-world clinical practice is still scarce, especially in Asian population. Objective: First, to analyze the prescription patterns of oral antithrombotic agents after the launch of NOACs. Second, to assess the effectiveness and safety between patients who newly initiated NOAC and warfarin among Asian population. Third, we aim to evaluate whether being long-term prescribed warfarin would affect the effectiveness and safety of NOAC. Methods: We used National Health Insurance Research Database (NHIRD) to assess non-valvular atrial fibrillation patients who prescribed dabigatran, rivaroxaban, or warfarin from Jun 1st, 2012 to Dec 31th, 2015. We applied propensity score matching to the Cox proportional hazard model to evaluate the effectiveness and safety between NOACs (including dabigatran and rivaroxaban) and warfarin. The analyses were also repeated to assess different drug groups, dose groups, and elderly patients with at least 65 or 80 years old. The follow-up period was the time from index date to the outcome of interests, switching to or discontinuation of alternative oral anticoagulants, end of the administrative period. Results: Compared with warfarin in the warfarin-naive stratum, NOAC were generally associated with a lower risk of intracranial hemorrhage (HR: 0.45, 95% CI: 0.31-0.66), venous thromboembolism (HR: 0.37, 95% CI: 0.21-0.66), and the composite bleeding events (HR: 0.8, 95% CI: 0.69-0.92), whereas there were no significant differences in 3 the risk of gastrointestinal bleeding. In different dose groups, rivaroxaban 20 mg and 15 mg were associated with a lower risk of ischemic stroke compared with warfarin (HR:0.48, 95%: 0.29-0.80 and HR: 0.69, 95% CI: 0.53-0.90 in rivaroxaban 20 mg and 15 mg, respectively), and rivaroxaban 20 mg was associated with a lower risk of gastrointestinal bleeding (HR:0.47, 95% CI: 0.24-0.90). In elderly, rivaroxaban was associated with lower risk of ischemic stroke compared with warfarin in patients with at least 65 years old (HR: 0.71, 95% CI: 0.56-0.89) and 80 years old (HR: 0.65, 95% 0.46-0.61). In warfarin-experienced stratum, NOAC was associated with lower risk of intracranial hemorrhage (HR: 0.38, 95% CI: 0.19-0.78). However, there were no significant differences in the risk of ischemic stroke, transient ischemic attack, venous thromboembolism, and gastrointestinal bleeding. Conclusions: In the ─real-world∥ clinical practice, NOACs were generally associated with a lower risk of intracranial hemorrhage compared with warfarin. Rivaroxaban with a dose equal to or greater than 15 mg may be considered as a sufficient therapeutic dose in preventing thromboembolism events. Moreover, rivaroxaban was found to be a better choice than warfarin in preventing ischemic stroke among elderly patients.
主题分类 醫藥衛生 > 藥理醫學
醫學院 > 臨床藥學研究所
参考文献
  1. 1. Lip GY, Boos CJ. Antithrombotic treatment in atrial fibrillation. Heart (British Cardiac Society). 2006;92:155-161
    連結：
  2. 2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: A major contributor to stroke in the elderly. The framingham study. Arch Intern Med. 1987;147:1561-1564
    連結：
  3. 3. Keeling D, Baglin T, Tait C, Watson H, Perry D, Baglin C, Kitchen S, Makris M, British Committee for Standards in H. Guidelines on oral anticoagulation with warfarin - fourth edition. British journal of haematology. 2011;154:311-324
    連結：
  4. 4. Silva RMFLd. Novel oral anticoagulants in non-valvular atrial fibrillation. Cardiovascular & Hematological Agents in Medicinal Chemistry. 2014;12:3-8
    連結：
  5. 5. Gonzalez-Quesada CJ, Giugliano RP. Comparison of the phase iii clinical trial designs of novel oral anticoagulants versus warfarin for the treatment of nonvalvular atrial fibrillation: Implications for clinical practice. American journal of cardiovascular drugs : drugs, devices, and other interventions. 2014;14:111-127
    連結：
  6. 8. Larsen TB, Rasmussen LH, Skjoth F, Due KM, Callreus T, Rosenzweig M, Lip GY. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: A prospective nationwide cohort study. Journal of the American College of Cardiology. 2013;61:2264-2273
    連結：
  7. 9. Lauffenburger JC, Farley JF, Gehi AK, Rhoney DH, Brookhart MA, Fang G. Effectiveness and safety of dabigatran and warfarin in real-world us patients with non-valvular atrial fibrillation: A retrospective cohort study. Journal of the American Heart Association. 2015;4
    連結：
  8. 10. Maura G, Blotiere PO, Bouillon K, Billionnet C, Ricordeau P, Alla F, Zureik M. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin k antagonists: A french nationwide propensity-matched cohort study. Circulation. 2015;132:1252-1260
    連結：
  9. 11. Seeger JD, Bykov K, Bartels DB, Huybrechts K, Zint K, Schneeweiss S. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. Thrombosis and haemostasis. 2015;115
    連結：
  10. 12. Villines TC, Schnee J, Fraeman K, Siu K, Reynolds MW, Collins J, Schwartzman E. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system. Thrombosis and haemostasis. 2015;115
    連結：
  11. 13. Larsen TB, Gorst-Rasmussen A, Rasmussen LH, Skjoth F, Rosenzweig M, Lip GY. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. The American journal of medicine. 2014;127:650-656 e655
    連結：
  12. 15. Chan YH, Yen KC, See LC, Chang SH, Wu LS, Lee HF, Tu HT, Yeh YH, Kuo CT. Cardiovascular, bleeding, and mortality risks of dabigatran in asians with nonvalvular atrial fibrillation. Stroke; a journal of cerebral circulation. 2016;47:441-449
    連結：
  13. 16. Lin YP, Tan TY. Do noacs improve antithrombotic therapy in secondary stroke prevention in nonvalvular atrial fibrillation? Medicine. 2015;94:e1627
    連結：
  14. the management of patients with atrial fibrillation: Executive summary. Journal of the American College of Cardiology. 2014;64:2246-2280
    連結：
  15. 18. Page RL, Wilkinson WE, Clair WK, McCarthy EA, Pritchett EL. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation. 1994;89:224-227
    連結：
  16. 19. Chien KL, Su TC, Hsu HC, Chang WT, Chen PC, Chen MF, Lee YT. Atrial fibrillation prevalence, incidence and risk of stroke and all-cause death among
    連結：
  17. fibrillation management in asia: From the asian expert forum on atrial
    連結：
  18. fibrillation. International journal of cardiology. 2013;164:21-32
    連結：
  19. 21. Sanoski CA. Clinical, economic, and quality of life impact of atrial fibrillation.
    連結：
  20. Journal of managed care pharmacy : JMCP. 2009;15:S4-9
    連結：
  21. 22. Singh SN. Costs and clinical consequences of suboptimal atrial fibrillation
    連結：
  22. Mortality trends in patients diagnosed with first atrial fibrillation: A 21-year community-based study. Journal of the American College of Cardiology. 2007;49:986-992
    連結：
  23. 24. B. EJ, W. PA, D. RB, S. H, K. WB, L. D. Impact of atrial fibrillation on the risk of death the framingham heart study. Circulation. 1998;98:946-952
    連結：
  24. 26. Kim MH, Johnston SS, Chu BC, Dalal MR, Schulman KL. Estimation of total incremental health care costs in patients with atrial fibrillation in the united states. Circulation. Cardiovascular quality and outcomes. 2011;4:313-320
    連結：
  25. 28. Yiin GS, Howard DP, Paul NL, Li L, Luengo-Fernandez R, Bull LM, Welch SJ, Gutnikov SA, Mehta Z, Rothwell PM. Age-specific incidence, outcome, cost, and projected future burden of atrial fibrillation-related embolic vascular events: A population-based study. Circulation. 2014;130:1236-1244
    連結：
  26. 29. Chugh SS, Roth GA, Gillum RF, Mensah GA. Global burden of atrial fibrillation in developed and developing nations. Global heart. 2014;9:113-119
    連結：
  27. 30. Bhatt HV, Fischer GW. Atrial fibrillation: Pathophysiology and therapeutic options. Journal of cardiothoracic and vascular anesthesia. 2015;29:1333-1340
    連結：
  28. Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW, Members AATF. 2014 aha/acc/hrs guideline for the management of patients with atrial fibrillation: A report of the american college of cardiology/american heart association task force on practice guidelines and the heart rhythm society. Circulation. 2014;130:e199-267
    連結：
  29. 32. Wolf PA, Benjamin EJ, Belanger AJ, Kannel WB, Levy D, D'Agostino RB. Secular trends in the prevalence of atrial fibrillation: The framingham study. American heart journal. 1996;131:790-795
    連結：
  30. 33. Huxley RR, Lopez FL, Folsom AR, Agarwal SK, Loehr LR, Soliman EZ, Maclehose R, Konety S, Alonso A. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: The atherosclerosis risk in communities (aric) study. Circulation. 2011;123:1501-1508
    連結：
  31. 34. Chamberlain AM, Agarwal SK, Folsom AR, Soliman EZ, Chambless LE, Crow R, Ambrose M, Alonso A. A clinical risk score for atrial fibrillation in a biracial prospective cohort (from the atherosclerosis risk in communities [aric] study). The American journal of cardiology. 2011;107:85-91
    連結：
  32. 35. Lip GYH, Tse H-F. Management of atrial fibrillation. The Lancet. 2007;370:604-618
    連結：
  33. 36. Lip GYH, Tse HF, Lane DA. Atrial fibrillation. The Lancet. 2012;379:648-661
    連結：
  34. 37. Olshansky B, Rosenfeld LE, Warner AL, Solomon AJ, O'Neill G, Sharma A,
    連結：
  35. Platia E, Feld GK, Akiyama T, Brodsky MA, Greene HL. The atrial fibrillation follow-up investigation of rhythm management (affirm) study: Approaches to control rate in atrial fibrillation. Journal of the American College of Cardiology. 2004;43:1201-1208
    連結：
  36. 38. Gao Q, Fu X, Wei JW, Chen X, Huang Y, Wang J, Anderson CS, Wong KS, China QSI. Use of oral anticoagulation among stroke patients with atrial fibrillation in china: The chinaquest (quality evaluation of stroke care and treatment) registry study. International journal of stroke : official journal of the International Stroke Society. 2013;8:150-154
    連結：
  37. Antithrombotic treatment patterns in 10,871 patients with newly diagnosed nonvalvular atrial fibrillation: The gloria-af registry, phase ii. The American journal of medicine. 2015
    連結：
  38. 40. Marini C, De Santis F, Sacco S, Russo T, Olivieri L, Totaro R, Carolei A. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: Results from a population-based study. Stroke; a journal of cerebral circulation. 2005;36:1115-1119
    連結：
  39. 41. Jorgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Acute stroke with atrial fibrillation. The copenhagen stroke study. Stroke; a journal of cerebral circulation. 1996;27:1765-1769
    連結：
  40. 42. Yang Y, Zhang Z, Ng CY, Li G, Liu T. Meta-analysis of chads2 score in predicting atrial fibrillation. The American journal of cardiology. 2015;116:554-562
    連結：
  41. 43. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P, Guidelines ESCCfP. 2012 focused update of the esc guidelines for the management of atrial fibrillation: An update of the 2010 esc guidelines for the management of atrial fibrillation. Developed with the special contribution of the european heart rhythm association. European heart journal. 2012;33:2719-2747
    連結：
  42. 44. Xiong Q, Chen S, Senoo K, Proietti M, Hong K, Lip GY. The chads2 and cha2ds2-vasc scores for predicting ischemic stroke among east asian patients with atrial fibrillation: A systemic review and meta-analysis. International journal of cardiology. 2015;195:237-242
    連結：
  43. 45. Barnes GD, Gu X, Haymart B, Kline-Rogers E, Almany S, Kozlowski J, Besley D, Krol GD, Froehlich JB, Kaatz S. The predictive ability of the chads2 and cha2ds2-vasc scores for bleeding risk in atrial fibrillation: The maqi(2) experience. Thrombosis research. 2014;134:294-299
    連結：
  44. 46. Lip GY, Halperin JL. Improving stroke risk stratification in atrial fibrillation. The American journal of medicine. 2010;123:484-488
    連結：
  45. 47. Mant J, Hobbs FDR, Fletcher K, Roalfe A, Fitzmaurice D, Lip GYH, Murray E. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the birmingham atrial fibrillation treatment of the aged study, bafta): A randomised controlled trial. The Lancet. 2007;370:493-503
    連結：
  46. 48. Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S CS. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (active w): A randomised controlled trial. The Lancet. 2006;367:1903-1912
    連結：
  47. 49. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin k antagonists: The seventh accp conference on antithrombotic and thrombolytic therapy. Chest. 2004;126:204s-233s
    連結：
  48. 50. Sconce EA, Kamali F. Appraisal of current vitamin k dosing algorithms for the reversal of over-anticoagulation with warfarin: The need for a more tailored dosing regimen. European journal of haematology. 2006;77:457-462
    連結：
  49. 52. Gaikwad T, Ghosh K, Shetty S. Vkorc1 and cyp2c9 genotype distribution in asian countries. Thrombosis research. 2014;134:537-544
    連結：
  50. 53. Guidelines for pharmacotherapy of atrial fibrillation (jcs 2008): Digest version. Circulation journal : official journal of the Japanese Circulation Society. 2010;74:2479-2500
    連結：
  51. 54. Atarashi H, Inoue H, Okumura K, Yamashita T, Kumagai N, Origasa H. Present status of anticoagulation treatment in japanese patients with atrial fibrillation: A report from the j-rhythm registry. Circulation journal : official journal of the Japanese Circulation Society. 2011;75:1328-1333
    連結：
  52. 55. Kuo LN, Liou JP, Chen HY, Chiang YC, Wu MT. Evaluation of the safety and efficacy of warfarin in taiwanese patients. International journal of clinical pharmacology and therapeutics. 2013;51:106-113
    連結：
  53. 56. Wen-Hang QI, Society of Cardiology CMA. Retrospective investigation of hospitalised patients with atrial fibrillation in mainland china. International journal of cardiology. 2005;105:283-287
    連結：
  54. Halperin JL, Becker RC, Breithardt G, Hankey GJ, Hacke W, Nessel CC, Patel MR, Califf RM, Fox KA, Investigators RA. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: Data from the rocket af clinical trial. Journal of the American Heart Association. 2013;2:e000067
    連結：
  55. 59. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, Pais P, Dans A, Eikelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: An analysis of the re-ly trial. Lancet (London, England). 2010;376:975-983
    連結：
  56. 60. Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. Journal of the American College of Cardiology. 2007;50:309-315
    連結：
  57. 61. Guo Y, Pisters R, Apostolakis S, Blann AD, Wang H, Zhao X, Zhang Y, Zhang D, Ma J, Wang Y, Lip GY. Stroke risk and suboptimal thromboprophylaxis in chinese patients with atrial fibrillation: Would the novel oral anticoagulants have an impact? International journal of cardiology. 2013;168:515-522
    連結：
  58. 73. Furie KL, Goldstein LB, Albers GW, Khatri P, Neyens R, Turakhia MP, Turan TN, Wood KA, American Heart Association Stroke C, Council on Quality of C, Outcomes R, Council on Cardiovascular N, Council on Clinical C, Council on Peripheral Vascular D. Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: A science advisory for healthcare professionals from the american heart association/american stroke association. Stroke; a journal of cerebral circulation. 2012;43:3442-3453
    連結：
  59. 74. 衛生福利部中央健康保險署藥品給付規定(更新日期 2015/12/07) http://www.Nhi.Gov.Tw/webdata/webdata.Aspx?Menu=8&menu_id=498&webd ata_id=2919.
    連結：
  60. 75. Patel PA, Zhao X, Fonarow GC, Lytle BL, Smith EE, Xian Y, Bhatt DL, Peterson ED, Schwamm LH, Hernandez AF. Novel oral anticoagulant use among patients with atrial fibrillation hospitalized with ischemic stroke or transient ischemic attack. Circulation. Cardiovascular quality and outcomes. 2015;8:383-392
    連結：
  61. 76. Weitz JI, Semchuk W, Turpie AG, Fisher WD, Kong C, Ciaccia A, Cairns JA. Trends in prescribing oral anticoagulants in canada, 2008-2014. Clinical therapeutics. 2015
    連結：
  62. 78. Tagaya M, Yoshikawa D, Sugishita Y, Yamauchi F, Ito T, Kamada T, Yoshinaga M, Mukaide D, Fujiwara W, Yokoi H, Hayashi M, Watanabe E, Ishii J, Ozaki Y, Izawa H. Prescription patterns of oral anticoagulants for patients with non-valvular atrial fibrillation: Experience at a japanese single institution. Heart and vessels. 2015
    連結：
  63. 79. Xu Y, Holbrook AM, Simpson CS, Dowlatshahi D, Johnson AP. Prescribing patterns of novel oral anticoagulants following regulatory approval for atrial fibrillation in ontario, canada: A population-based descriptive analysis. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2013;1:E115-E119
    連結：
  64. 80. Huisman MV, Lip GY, Diener HC, Dubner SJ, Halperin JL, Ma CS, Rothman KJ, Teutsch C, Zint K, Ackermann D, Clemens A, Bartels DB. Design and rationale of global registry on long-term oral antithrombotic treatment in patients with atrial fibrillation: A global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation. American heart journal. 2014;167:329-334
    連結：
  65. 82. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. The Lancet. 2014;383:955-962
    連結：
  66. 83. Abraham NS, Singh S, Alexander GC, Heien H, Haas LR, Crown W, Shah ND. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: Population based cohort study. Bmj. 2015;350:h1857
    連結：
  67. 84. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115:2689-2696
    連結：
  68. 85. Garcia DA, Lopes RD, Hylek EM. New-onset atrial fibrillation and warfarin initiation: High risk periods and implications for new antithrombotic drugs. Thrombosis and haemostasis. 2010;104:1099-1105
    連結：
  69. 86. Larsen TB, Rasmussen LH, Gorst-Rasmussen A, Skjoth F, Lane DA, Lip GY. Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: A nationwide cohort study. The American journal of medicine. 2014;127:1172-1178 e1175
    連結：
  70. 87. Ezekowitz MD, Wallentin L, Connolly SJ, Parekh A, Chernick MR, Pogue J, Aikens TH, Yang S, Reilly PA, Lip GY, Yusuf S, Committee R-LS, Investigators. Dabigatran and warfarin in vitamin k antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation. 2010;122:2246-2253
    連結：
  71. 89. Hernandez I, Baik SH, Pinera A, Zhang Y. Risk of bleeding with dabigatran in atrial fibrillation. JAMA internal medicine. 2015;175:18-24
    連結：
  72. 90. Lauffenburger JC, Rhoney DH, Farley JF, Gehi AK, Fang G. Predictors of gastrointestinal bleeding among patients with atrial fibrillation after initiating dabigatran therapy. Pharmacotherapy. 2015;35:560-568
    連結：
  73. 91. Shen AY, Yao JF, Brar SS, Jorgensen MB, Wang X, Chen W. Racial/ethnic differences in ischemic stroke rates and the efficacy of warfarin among patients with atrial fibrillation. Stroke; a journal of cerebral circulation. 2008;39:2736-2743
    連結：
  74. 93. Laliberte F, Cloutier M, Nelson WW, Coleman CI, Pilon D, Olson WH, Damaraju CV, Schein JR, Lefebvre P. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Current medical research and opinion. 2014;30:1317-1325
    連結：
  75. 95. Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Capra AM, Jensvold NG, Selby JV, Singer DE. Anticoagulation therapy for stroke prevention in atrial fibrillation: How well do randomized trials translate into clinical practice? Jama. 2003;290:2685-2692
    連結：
  76. 97. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, 3rd, Guyton RA, O'Gara PT, Ruiz CE, Skubas NJ, Sorajja P, Sundt TM, 3rd, Thomas JD, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Creager MA, Curtis LH, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Stevenson WG, Yancy CW. 2014 aha/acc guideline for the management of patients with valvular heart disease: A report of the american college of cardiology/american heart association task force on practice guidelines. The Journal of thoracic and cardiovascular surgery. 2014;148:e1-e132
    連結：
  77. 98. Komenda P, Yu N, Leung S, Bernstein K, Blanchard J, Sood M, Rigatto C, Tangri N. Secular trends in end-stage renal disease requiring dialysis in manitoba, canada: A population-based study. CMAJ open. 2015;3:E8-E14
    連結：
  78. 100. Self TH, Owens RE, Sakaan SA, Wallace JL, Sands CW, Howard-Thompson A. Effect of diseases on response to vitamin k antagonists. Current medical research and opinion. 2015:1-30
    連結：
  79. 101. Kumamaru H, Judd SE, Curtis JR, Ramachandran R, Hardy NC, Rhodes JD, Safford MM, Kissela BM, Howard G, Jalbert JJ, Brott TG, Setoguchi S. Validity of claims-based stroke algorithms in contemporary medicare data: Reasons for geographic and racial differences in stroke (regards) study linked with medicare claims. Circulation. Cardiovascular quality and outcomes. 2014;7:611-619
    連結：
  80. 102. Kokotailo RA, Hill MD. Coding of stroke and stroke risk factors using international classification of diseases, revisions 9 and 10. Stroke; a journal of cerebral circulation. 2005;36:1776-1781
    連結：
  81. 103. Tamariz L, Harkins T, Nair V. A systematic review of validated methods for identifying venous thromboembolism using administrative and claims data. Pharmacoepidemiology and drug safety. 2012;21 Suppl 1:154-162
    連結：
  82. 104. Andrade SE, Harrold LR, Tjia J, Cutrona SL, Saczynski JS, Dodd KS, Goldberg RJ, Gurwitz JH. A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data. Pharmacoepidemiology and drug safety. 2012;21 Suppl 1:100-128
    連結：
  83. 105. Cheng CL, Kao YH, Lin SJ, Lee CH, Lai ML. Validation of the national health insurance research database with ischemic stroke cases in taiwan. Pharmacoepidemiology and drug safety. 2011;20:236-242
    連結：
  84. 106. Hsieh CY, Chen CH, Li CY, Lai ML. Validating the diagnosis of acute ischemic stroke in a national health insurance claims database. Journal of the Formosan
    連結：
  85. Graham J. Bleeding as an outcome among patients with nonvalvular atrial fibrillation in a large managed care population. Clinical therapeutics. 2013;35:1536-1545 e1531
    連結：
  86. 108. Cunningham A, Stein CM, Chung CP, Daugherty JR, Smalley WE, Ray WA. An automated database case definition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiology and drug safety. 2011;20:560-566
    連結：
  87. 109. Wahl PM, Rodgers K, Schneeweiss S, Gage BF, Butler J, Wilmer C, Nash M, Esper G, Gitlin N, Osborn N, Short LJ, Bohn RL. Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured population. Pharmacoepidemiology and drug safety. 2010;19:596-603
    連結：
  88. Go AS. Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation?: The atria study. Circulation. Cardiovascular quality and outcomes. 2009;2:297-304
    連結：
  89. 112. Lauffenburger JC, Farley JF, Gehi AK, Rhoney DH, Brookhart MA, Fang G. Factors driving anticoagulant selection in patients with atrial fibrillation in the united states. The American journal of cardiology. 2015;115:1095-1101
    連結：
  90. 113. AbuDagga A, Fu JJSA-C, Kwong WJ, Tan H, Weintraub WS. Characteristics affecting oral anticoagulant therapy choice among patients with non-valvular atrial fibrillation: A retrospective claims analysis. BMC Health Services Research 2014;14:310
    連結：
  91. 114. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA. Coding algorithms for defining comorbidities in icd-9-cm and icd-10 administrative data. Med Care. 2005;43:1130-1139
    連結：
  92. 115. Lin CC, Lai MS, Syu CY, Chang SC, Tseng FY. Accuracy of diabetes diagnosis in health insurance claims data in taiwan. Journal of the Formosan Medical Association = Taiwan yi zhi. 2005;104:157-163
    連結：
  93. 116. Melgaard L, Gorst-Rasmussen A, Lane DA, Rasmussen LH, Larsen TB, Lip GY. Assessment of the cha2ds2-vasc score in predicting ischemic stroke, thromboembolism, and death in patients with heart failure with and without atrial fibrillation. Jama. 2015;314:1030-1038
    連結：
  94. 117. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation. Chest. 2010;137:263-272
    連結：
  95. 118. Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, Selmer C, Ahlehoff O, Olsen AM, Gislason GH, Torp-Pedersen C. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: Nationwide cohort study. Bmj. 2011;342:d124
    連結：
  96. 119. Olesen JB, Lip GY, Hansen PR, Lindhardsen J, Ahlehoff O, Andersson C, Weeke P, Hansen ML, Gislason GH, Torp-Pedersen C. Bleeding risk in 'real world' patients with atrial fibrillation: Comparison of two established bleeding prediction schemes in a nationwide cohort. Journal of thrombosis and haemostasis : JTH. 2011;9:1460-1467
    連結：
  97. 120. Staerk L, Lip GY, Olesen JB, Fosbol EL, Pallisgaard JL, Bonde AN, Gundlund A, Lindhardt TB, Hansen ML, Torp-Pedersen C, Gislason GH. Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: Nationwide cohort study. Bmj. 2015;351:h5876
    連結：
  98. 121. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Statistics in medicine. 2009;28:3083-3107
    連結：
  99. 122. Cohen J. Statistical power analysis of the behavioral sciences. (2nd ed.). New york: Academic press. 1988
    連結：
  100. 123. Hori M, Connolly SJ, Zhu J, Liu LS, Lau CP, Pais P, Xavier D, Kim SS, Omar R, Dans AL, Tan RS, Chen JH, Tanomsup S, Watanabe M, Koyanagi M, Ezekowitz MD, Reilly PA, Wallentin L, Yusuf S. Dabigatran versus warfarin: Effects on ischemic and hemorrhagic strokes and bleeding in asians and non-asians with atrial fibrillation. Stroke; a journal of cerebral circulation. 2013;44:1891-1896
    連結：
  101. 124. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. The New England journal of medicine. 2009;361:2342-2352
    連結：
  102. 127. Hori M, Connolly SJ, Zhu J, Liu LS, Lau CP, Pais P, Xavier D, Kim SS, Omar R, Dans AL, Tan RS, Chen JH, Tanomsup S, Watanabe M, Koyanagi M, Ezekowitz MD, Reilly PA, Wallentin L, Yusuf S, Investigators R-L. Dabigatran versus warfarin: Effects on ischemic and hemorrhagic strokes and bleeding in asians and non-asians with atrial fibrillation. Stroke; a journal of cerebral circulation. 2013;44:1891-1896
    連結：
  103. 128. Kundu A, Sardar P, Chatterjee S, Aronow WS, Owan T, Ryan JJ. Minimizing the risk of bleeding with noacs in the elderly. Drugs & aging. 2016
    連結：
  104. 130. Ntaios G, Papavasileiou V, Diener HC, Makaritsis K, Michel P. Nonvitamin-k-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: A systematic review and meta-analysis of randomized controlled trials. Stroke; a journal of cerebral circulation. 2012;43:3298-3304
    連結：
  105. 131. Diener HC. Pro: "The novel oral anticoagulants should be used as 1st choice for secondary prevention in patients with atrial fibrillation.". Thrombosis and haemostasis. 2013;110:493-495
    連結：
  106. 132. Lee CH, Lin LJ, Cheng CL, Kao Yang YH, Chen JY, Tsai LM. Incidence and cumulative recurrence rates of venous thromboembolism in the taiwanese population. Journal of thrombosis and haemostasis : JTH. 2010;8:1515-1523
    連結：
  107. 6. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. The New England journal of medicine. 2009;361:1139-1151
  108. 7. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. The New England journal of medicine. 2011;365:883-891
  109. 14. Chan PH, Huang D, Hai J, Li WH, Yin LX, Chan EW, Wong IC, Lau CP, Chiang CE, Zhu J, Tse HF, Siu CW. Stroke prevention using dabigatran in the very elderly with atrial fibrillation. Heart rhythm : the official journal of the Heart Rhythm Society. 2015
  110. 17. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW. 2014 aha/acc/hrs guideline for
  111. chinese. International journal of cardiology. 2010;139:173-180
  112. 20. Chiang CE, Zhang S, Tse HF, Teo WS, Omar R, Sriratanasathavorn C. Atrial
  113. management. ClinicoEconomics and outcomes research : CEOR. 2012;4:79-90
  114. 23. Miyasaka Y, Barnes ME, Bailey KR, Cha SS, Gersh BJ, Seward JB, Tsang TS.
  115. 25. Taggar JS, Marin F, Lip GY. Mortality in patients with atrial fibrillation: Improving or not? Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 2008;10:389-390
  116. 27. Heemstra HE, Nieuwlaat R, Meijboom M, Crijns HJ. The burden of atrial fibrillation in the netherlands. Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation. 2011;19:373-378
  117. 31. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, Jr.,
  118. 39. Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma C, Zint K, Elsaesser A, Bartels DB, Lip GY, Investigators G-A.
  119. 138
  120. 51. Zhao F, Loke C, Rankin SC, Guo JY, Lee HS, Wu TS, Tan T, Liu TC, Lu WL, Lim YT, Zhang Q, Goh BC, Lee SC. Novel cyp2c9 genetic variants in asian subjects and their influence on maintenance warfarin dose. Clinical pharmacology and therapeutics. 2004;76:210-219
  121. 57. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Siegbahn A, Verheugt FW, Weitz JI, Coordinating C. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: Esc working group on thrombosis-task force on anticoagulants in heart disease position paper. Journal of the American College of Cardiology. 2012;59:1413-1425
  122. 58. Singer DE, Hellkamp AS, Piccini JP, Mahaffey KW, Lokhnygina Y, Pan G,
  123. 62. Boehringer ingelheim. PradaxaR (dabigatran etexilate mesylate) capsules prescribing information. Ridgefield, ct. 2014 aug.
  124. 63. Gerald k. Mcevoy, pharm.D., ed. 2015. Ahfs drug informationR - 56th ed. Bethesda, md. American society of health-system pharmacists. Isbn-10: 1-58528-380-0, isbn-13: 978-1-58528-380-4. Stat!Ref online electronic medical library. Http://online.Statref.Com/document.Aspx?Fxid=1&docid=474. 11/14/2015 8:55:59 pm cst (utc -06:00).
  125. 64. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P, European Heart Rhythm A. European heart rhythm association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 2013;15:625-651
  126. 65. Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P, Advisors. Updated european heart rhythm association practical guide on the use of non-vitamin k antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 2015;17:1467-1507
  127. 66. Pollack CV, Jr., Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI. Idarucizumab for dabigatran reversal. The New England journal of medicine. 2015;373:511-520
  128. 67. Janssen. XareltoR (rivaroxaban) oral tablets prescribing information. Titusville, nj: 2014 mar.
  129. 68. Gerald k. Mcevoy, pharm.D., ed. 2015. Ahfs drug informationR - 56th ed. Bethesda, md. American society of health-system pharmacists. Isbn-10: 1-58528-380-0, isbn-13: 978-1-58528-380-4. Stat!Ref online electronic medical library. Http://online.Statref.Com/document.Aspx?Fxid=1&docid=479. 11/14/2015 11:12:43 pm cst (utc -06:00).
  130. 69. Hori M, Matsumoto M, Tanahashi N, Momomura S-i, Uchiyama S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iwamoto K, Tajiri M. Rivaroxaban vs. Warfarin in japanese patients with atrial fibrillation. Circulation Journal. 2012;76:2104-2111
  131. 70. Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, Mathur VS, Castillo J, Bronson MD, Leeds JM, Mar FA, Gold A, Crowther MA. Andexanet alfa for the reversal of factor xa inhibitor activity. The New England journal of medicine. 2015
  132. 71. Gerald k. Mcevoy, pharm.D., ed. 2015. Ahfs drug informationR - 56th ed. Bethesda, md. American society of health-system pharmacists. Isbn-10: 1-58528-380-0, isbn-13: 978-1-58528-380-4. Stat!Ref online electronic medical library. Http://online.Statref.Com/document.Aspx?Fxid=1&docid=477. 11/15/2015 1:17:29 am cst (utc -06:00).
  133. 72. Bristol-myers squibb. EliquisR (apixaban) oral tablets prescribing information. Princeton, nj: 2014 aug.
  134. 77. Toyoda K, Arihiro S, Todo K, Yamagami H, Kimura K, Furui E, Terasaki T, Shiokawa Y, Kamiyama K, Takizawa S, Okuda S, Okada Y, Kameda T, Nagakane Y, Hasegawa Y, Mochizuki H, Ito Y, Nakashima T, Takamatsu K, Nishiyama K, Kario K, Sato S, Koga M. Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in japan: The samurai-nvaf study. International journal of stroke : official journal of the International Stroke Society. 2015;10:836-842
  135. 81. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L. Apixaban versus warfarin in patients with atrial fibrillation. The New England journal of medicine. 2011;365:981-992
  136. 88. Wong KS, Hu DY, Oomman A, Tan RS, Patel MR, Singer DE, Breithardt G, Mahaffey KW, Becker RC, Califf R, Fox KA, Berkowitz SD, Hacke W, Hankey GJ, Executive Steering C, the RAFSI. Rivaroxaban for stroke prevention in east asian patients from the rocket af trial. Stroke; a journal of cerebral circulation. 2014;45:1739-1747
  137. 92. Zhang LF, Yang J, Hong Z, Yuan GG, Zhou BF, Zhao LC, Huang YN, Chen J, Wu YF. Proportion of different subtypes of stroke in china. Stroke; a journal of cerebral circulation. 2003;34:2091-2096
  138. 94. National health insurance administration, ministry of health and welfare, taiwan, r.O.C. (2014). National health insurance annual report 2014-2015.
  139. 96. Fauchier L, Philippart R, Clementy N, Bourguignon T, Angoulvant D, Ivanes F, Babuty D, Bernard A. How to define valvular atrial fibrillation? Archives of cardiovascular diseases. 2015;108:530-539
  140. 99. Chao PW, Ou SM, Chen YT, Lee YJ, Wang FM, Liu CJ, Yang WC, Chen TJ, Chen TW, Li SY. Acute appendicitis in patients with end-stage renal disease. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract. 2012;16:1940-1946
  141. Medical Association = Taiwan yi zhi. 2015;114:254-259
  142. 107. Deitelzweig SB, Pinsky B, Buysman E, Lacey M, Makenbaeva D, Wiederkehr D,
  143. 110. National health insurance research database, taiwan.
  144. Http://nhird.Nhri.Org.Tw/en/index.Htm.
  145. 111. Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N,
  146. 125. Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E,
  147. Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. The New England journal of medicine. 2012;366:1287-1297
  148. 126. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S. Oral rivaroxaban for symptomatic venous thromboembolism. The New England journal of medicine. 2010;363:2499-2510
  149. 129. Bahrmann P, Harms F, Schambeck CM, Wehling M, Flohr J. [new oral anticoagulants for prophylaxis of stroke : Results of an expert conference on practical use in geriatric patients]. Zeitschrift fur Gerontologie und Geriatrie. 2016;49:216-226
print cancel